Clinical Trials Logo

Corticobasal Syndrome (CBS) clinical trials

View clinical trials related to Corticobasal Syndrome (CBS).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05983588 Recruiting - Clinical trials for Corticobasal Syndrome (CBS)

PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)

PROFIL
Start date: December 12, 2023
Phase: Phase 2
Study type: Interventional

Corticobasal syndrome (CBS) is a rapidly progressive neurodegenerative disorder with an average survival time of about 6-8 years after the first clinical manifestation. No potent symptomatic treatment is currently available. A disease-modifying therapy does not exist either. Neuroinflammation is key to the pathogenesis in neurodegenerative diseases with Tau- and/or AD-pathology. There is strong evidence that phenylbutyrate can modulate microglial function by enhancing their phagocytic activity, most likely by epigenetic mechanisms. So the main goal of this clinical trial is to study a potential disease-modifying effect of treatment with glycerol phenylbutyrate (GPB), which is a prodrug of phenylbutyric acid, for 26 weeks assessed by the levels of the biomarker neurofilament light chain (NfL) indicating disease progression in CBS. Given the aggressive nature of CBS, it is feasible to study effects of GPB on plasma NfL levels.

NCT ID: NCT04715399 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis(ALS)

UPenn Observational Research Repository on Neurodegenerative Disease

UNICORN
Start date: May 29, 2020
Phase:
Study type: Observational

The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.